Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...

In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...